Technology evaluation: HspE7 (Stressgen).

Article Details


Maciag PC, Paterson Y

Technology evaluation: HspE7 (Stressgen).

Curr Opin Mol Ther. 2005 Jun;7(3):256-63.

PubMed ID
15977424 [ View in PubMed

Stressgen is developing HspE7, a recombinant fusion protein comprising the human papillomavirus (HPV) E7 antigen and the heat shock protein Hsp65 from Mycobacterium bovis, as a potential therapy for conditions associated with HPV infection. This therapy is currently undergoing phase III clinical trials.

DrugBank Data that Cites this Article